Educational Activities

Show Filters
Hide Filters
1-2 of 2 Activities
Title
Availability
Format
Credits
Course Opens
Buttons
Live
Grand Rounds
1
04/09/2024 at 12:00 PM EST

Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation

Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs).  Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the number of patients with cancer who develop a VTE at some point during their treatment (around 15%).  CA-VTE is associated with decreased survival, increased morbidity and hospitalization, and the potential delay or interruption of systemic anti-cancer therapy.  During this series, our faculty will expand clinician knowledge of VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.

In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.  Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.

1
04/09/2024 at 12:00 PM EST

Alok A. Khorana, MD, FACP, FASCO

Alok A. Khorana, MD, FACP, FASCO

Professor of Medicine,
Cleveland Clinic Lerner College of Medicine,
Case Western Reserve University
Cleveland, OH

Live
Grand Rounds
1
03/15/2024 at 8:30 AM EST

Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation

Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs).  Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the number of patients with cancer who develop a VTE at some point during their treatment (around 15%).  CA-VTE is associated with decreased survival, increased morbidity and hospitalization, and the potential delay or interruption of systemic anti-cancer therapy.  During this series, our faculty will expand clinician knowledge of VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.

In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.  Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.

1
03/15/2024 at 8:30 AM EST

Robert D. McBane II, MD

Robert D. McBane II, MD